Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2015

01.07.2015 | Maternal-Fetal Medicine

Associations between pregnancy outcomes and unexplained high and low maternal serum alpha-fetoprotein levels

verfasst von: Pongsun Puntachai, Chanane Wanapirak, Supatra Sirichotiyakul, Fuanglada Tongprasert, Kasemsri Srisupundit, Suchaya Luewan, Kuntharee Traisrisilp, Theera Tongsong

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

To determine the relationship between adverse pregnancy outcomes and maternal serum alpha-fetoprotein (MSAFP) levels.

Materials and methods

A retrospective cohort study was conducted on consecutive singleton pregnancies, screened for fetal Down syndrome, in the northern part of Thailand. The prospective database of our fetal Down screening program was assessed to recruit all consecutive records. Pregnancies with medical complication and fetal abnormality were excluded. The recruited women were categorized into three groups: normal (≥0.76 to ≤2.0 MoM), low (<0.76 MoM) and high (>2.0 MoM) MSAFP levels.

Results

Of 7,110 screened women, 5,486 met inclusion criteria, including 240; 5,016 and 230 in the group of high, normal and low MSAFP levels, respectively. The rates of preterm birth, pregnancy-induced hypertension (PIH), fetal growth restriction (FGR), fetal death, low birth weight (LBW) and low APGAR scores were significantly higher in women with high MSAFP levels (11.7 vs. 6.6 %, 7.5 vs. 3.3 %, 7.5 vs. 3.3 %, 2.1 vs. 0.3 %, 15.8 vs. 6.7 %, and 2.9 vs. 0.5 % respectively), with relative risk of 1.76, 2.28, 2.27, 7.46, 2.35 and 6.09, respectively. The rates of preterm birth, FGR and LBW were significantly lower in low MSAFP levels with relative risk of 0.39, 0.26 and 0.26, respectively, whereas the rates of PIH and fetal death and low Apgar scores were not significantly different.

Conclusions

Pregnant women with high MSAFP levels had an increased risk of poor pregnancy outcomes, while those with low MSAFP levels had a significantly lower risk of such outcomes.
Literatur
1.
Zurück zum Zitat Mizejewski GJ (2007) Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. Exp Biol Med (Maywood) 232:993–1004CrossRef Mizejewski GJ (2007) Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. Exp Biol Med (Maywood) 232:993–1004CrossRef
2.
Zurück zum Zitat Morris RK, Cnossen JS, Langejans M et al (2008) Serum screening with Down’s syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 8:33CrossRefPubMedCentralPubMed Morris RK, Cnossen JS, Langejans M et al (2008) Serum screening with Down’s syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 8:33CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Mizejewski GJ (2004) Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med (Maywood) 229:439–463 Mizejewski GJ (2004) Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med (Maywood) 229:439–463
4.
Zurück zum Zitat Hay DM, Forrester PI, Hancock RL, Lorscheider FL (1976) Maternal serum alpha-fetoprotein in normal pregnancy. Br J Obstet Gynaecol 83:534–538CrossRefPubMed Hay DM, Forrester PI, Hancock RL, Lorscheider FL (1976) Maternal serum alpha-fetoprotein in normal pregnancy. Br J Obstet Gynaecol 83:534–538CrossRefPubMed
5.
Zurück zum Zitat Merkatz IR, Nitowsky HM, Macri JN, Johnson WE (1984) An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148:886–894CrossRefPubMed Merkatz IR, Nitowsky HM, Macri JN, Johnson WE (1984) An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148:886–894CrossRefPubMed
6.
Zurück zum Zitat Simpson JL, Palomaki GE, Mercer B et al (1995) Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Am J Obstet Gynecol 173:1742–1748CrossRefPubMed Simpson JL, Palomaki GE, Mercer B et al (1995) Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. Am J Obstet Gynecol 173:1742–1748CrossRefPubMed
7.
Zurück zum Zitat Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB (1996) The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88:816–822CrossRefPubMed Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB (1996) The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88:816–822CrossRefPubMed
8.
Zurück zum Zitat Spencer K (2000) Second-trimester prenatal screening for down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 20:652–656CrossRefPubMed Spencer K (2000) Second-trimester prenatal screening for down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 20:652–656CrossRefPubMed
9.
Zurück zum Zitat Wanapirak C, Sirichotiyakul S, Luewan S et al (2012) Different median levels of serum triple markers in the second trimester of pregnancy in a Thai Ethnic Group. J Obstet Gynaecol Res 38:686–691CrossRefPubMed Wanapirak C, Sirichotiyakul S, Luewan S et al (2012) Different median levels of serum triple markers in the second trimester of pregnancy in a Thai Ethnic Group. J Obstet Gynaecol Res 38:686–691CrossRefPubMed
10.
Zurück zum Zitat Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S (1996) Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies. Prenat Diagn 16:1129–1135CrossRefPubMed Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S (1996) Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies. Prenat Diagn 16:1129–1135CrossRefPubMed
11.
Zurück zum Zitat Milunsky A, Jick SS, Bruell CL et al (1989) Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol 161:291–297CrossRefPubMed Milunsky A, Jick SS, Bruell CL et al (1989) Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol 161:291–297CrossRefPubMed
12.
Zurück zum Zitat Raty R, Koskinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U (1999) Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels. Prenat Diagn 19:122–127CrossRefPubMed Raty R, Koskinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U (1999) Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels. Prenat Diagn 19:122–127CrossRefPubMed
13.
Zurück zum Zitat Wald NJ, Morris JK, Ibison J, Wu T, George LM (2006) Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 26:559–564CrossRefPubMed Wald NJ, Morris JK, Ibison J, Wu T, George LM (2006) Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 26:559–564CrossRefPubMed
14.
Zurück zum Zitat Dugoff L, Hobbins JC, Malone FD et al (2005) Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106:260–267CrossRefPubMed Dugoff L, Hobbins JC, Malone FD et al (2005) Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106:260–267CrossRefPubMed
15.
Zurück zum Zitat Capeless EL, Kelleher PC, Walters CP (1992) Elevated maternal serum alpha-fetoprotein levels and maternal risk factors. Their association with pregnancy complications. J Reprod Med 37:257–260PubMed Capeless EL, Kelleher PC, Walters CP (1992) Elevated maternal serum alpha-fetoprotein levels and maternal risk factors. Their association with pregnancy complications. J Reprod Med 37:257–260PubMed
16.
Zurück zum Zitat Morssink LP, Heringa MP, Beekhuis JR, De Wolf BT, Mantingh A (1997) The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and alpha-fetoprotein. Obstet Gynecol 89:666–670CrossRefPubMed Morssink LP, Heringa MP, Beekhuis JR, De Wolf BT, Mantingh A (1997) The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and alpha-fetoprotein. Obstet Gynecol 89:666–670CrossRefPubMed
17.
Zurück zum Zitat Cho S, Durfee KK, Keel BA, Parks LH (1997) Perinatal outcomes in a prospective matched pair study of pregnancy and unexplained elevated or low AFP screening. J Perinat Med 25:476–483CrossRefPubMed Cho S, Durfee KK, Keel BA, Parks LH (1997) Perinatal outcomes in a prospective matched pair study of pregnancy and unexplained elevated or low AFP screening. J Perinat Med 25:476–483CrossRefPubMed
18.
Zurück zum Zitat Pouta AM, Hartikainen AL, Vuolteenaho OJ, Ruokonen AO, Laatikainen TJ (1998) Midtrimester N-terminal proatrial natriuretic peptide, free beta hCG, and alpha-fetoprotein in predicting preeclampsia. Obstet Gynecol 91:940–944CrossRefPubMed Pouta AM, Hartikainen AL, Vuolteenaho OJ, Ruokonen AO, Laatikainen TJ (1998) Midtrimester N-terminal proatrial natriuretic peptide, free beta hCG, and alpha-fetoprotein in predicting preeclampsia. Obstet Gynecol 91:940–944CrossRefPubMed
19.
Zurück zum Zitat Hershkovitz R, de Swiet M, Kingdom J (2005) Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy 24:273–280CrossRefPubMed Hershkovitz R, de Swiet M, Kingdom J (2005) Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy 24:273–280CrossRefPubMed
20.
Zurück zum Zitat Brazerol WF, Grover S, Donnenfeld AE (1994) Unexplained elevated maternal serum alpha-fetoprotein levels and perinatal outcome in an urban clinic population. Am J Obstet Gynecol 171:1030–1035CrossRefPubMed Brazerol WF, Grover S, Donnenfeld AE (1994) Unexplained elevated maternal serum alpha-fetoprotein levels and perinatal outcome in an urban clinic population. Am J Obstet Gynecol 171:1030–1035CrossRefPubMed
21.
Zurück zum Zitat Society for Maternal-Fetal Medicine Publications Committee (2012) Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 206:376–386CrossRef Society for Maternal-Fetal Medicine Publications Committee (2012) Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 206:376–386CrossRef
22.
Zurück zum Zitat Burton BK (1988) Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 72:709–713PubMed Burton BK (1988) Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 72:709–713PubMed
23.
Zurück zum Zitat Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Norgaard-Pedersen B et al (2001) Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 97:277–282CrossRefPubMed Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Norgaard-Pedersen B et al (2001) Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 97:277–282CrossRefPubMed
24.
Zurück zum Zitat Baschat AA, Harman CR, Farid G, Chodirker BN, Evans JA (2002) Very low second-trimester maternal serum alpha-fetoprotein: association with high birth weight. Obstet Gynecol 99:531–536CrossRefPubMed Baschat AA, Harman CR, Farid G, Chodirker BN, Evans JA (2002) Very low second-trimester maternal serum alpha-fetoprotein: association with high birth weight. Obstet Gynecol 99:531–536CrossRefPubMed
Metadaten
Titel
Associations between pregnancy outcomes and unexplained high and low maternal serum alpha-fetoprotein levels
verfasst von
Pongsun Puntachai
Chanane Wanapirak
Supatra Sirichotiyakul
Fuanglada Tongprasert
Kasemsri Srisupundit
Suchaya Luewan
Kuntharee Traisrisilp
Theera Tongsong
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3606-9

Weitere Artikel der Ausgabe 1/2015

Archives of Gynecology and Obstetrics 1/2015 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.